(Q46820120)

25 December 2017

title

The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin (English)

1 reference

25 December 2017

1 reference

1 reference

Lin JC

1

1 reference

25 December 2017

Ito MK

2

1 reference

25 December 2017

Stolley SN

3

1 reference

25 December 2017

Morreale AP

4

1 reference

25 December 2017

Marcus DB

5

1 reference

25 December 2017

publication date

1 January 1999

1 reference

25 December 2017

The Journal of Clinical Pharmacology

published in

1 reference

25 December 2017

volume

39

1 reference

25 December 2017

issue

1

1 reference

25 December 2017

page(s)

86-90

1 reference

25 December 2017

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

cites work

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007598

Clinically important drug interactions with anticoagulants. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007598

Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007598

Plasma protein binding displacement interactions--why are they still regarded as clinically important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007598

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007598

Effects of extensive and poor gastrointestinal metabolism on the pharmacodynamics of pravastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007598

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007598

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007598

Pharmacokinetics of the enantiomers of acenocoumarol in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007598

Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007598

Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007598

10.1177/00912709922007598

21 January 2018

Identifiers

DOI

1 reference

25 December 2017

release_rnncvrna3nc7rmcyl4lfql3pam

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rnncvrna3nc7rmcyl4lfql3pam

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

9987704

1 reference

25 December 2017